Minerva (NERV)

Minerva Neurosciences' (NERV) CEO Dr. Remy Luthringer on Q3 2017 Results - Earnings Call Transcript
Nov. 6, 2017 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q2 2017 Results - Earnings Call Transcript
Aug. 5, 2017 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Tom Marano on Q1 2017 Results - Earnings Call Transcript
May 6, 2017 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q4 2016 Results - Earnings Call Transcript
March 13, 2017 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q3 2016 Results - Earnings Call Transcript
Nov. 3, 2016 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q2 2016 Results - Earnings Call Transcript
Aug. 7, 2016 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q1 2016 Results - Earnings Call Transcript
May 3, 2016 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q4 2015 Results - Earnings Call Transcript
March 14, 2016 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q3 2015 Results - Earnings Call Transcript
Nov. 7, 2015 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q2 2015 Results - Earnings Call Transcript
Aug. 9, 2015 | Price: Free! | Source: Seeking Alpha

Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q1 2015 Results -- Earnings Call Transcript
May 7, 2015 | Price: Free! | Source: Seeking Alpha

Minerva's (NERV) CEO Remy Luthringer on Q4 2014 Results - Earnings Call Transcript
March 26, 2015 | Price: Free! | Source: Seeking Alpha

Minerva's (NERV) CEO Dr. Rogerio Vivaldi on Q3 2014 Results - Earnings Call Transcript
Nov. 6, 2014 | Price: Free! | Source: Seeking Alpha

Recent filings

Minerva Just Filed Its Quarterly Report: NOTE 4 — NET LOSS P... - Nov. 6, 2017

into a Material Definitive - Oct. 6, 2017

Major owner of Minerva just disposed of 3,892,256 shares - Sept. 14, 2017

Statement of acquisition of beneficial ownership by individuals - Sept. 14, 2017

Departure of Directors or Principal - Sept. 8, 2017

Minerva's SVP and Head of R&D was just granted 100,000 options - Sept. 5, 2017

Minerva's SVP and Head of R&D just declared ownership of no shares of Minerva - Sept. 5, 2017

Minerva Neurosciences Announces European Commission Approval Of AMENDMENT OF MIN-202 AGREEMENT WITH JANSSEN - Aug. 25, 2017

Minerva Just Filed Its Quarterly Report: NOTE 4 — NET LOSS P... - Aug. 3, 2017

Minerva director was just granted 50,000 options - July 26, 2017

Minerva Neurosciences Announces Departure Of Directors - July 24, 2017

Minerva Neurosciences, Inc. To Offer Common Shares - June 29, 2017

Minerva just filed a prospectus, suggesting it plans to soon issue some securities - June 29, 2017

Minerva just filed a prospectus, suggesting it plans to soon issue some securities - June 27, 2017

Entry into a Material Definitive - June 14, 2017

Minerva director was just granted 12,500 options - June 5, 2017

Minerva director was just granted 12,500 options - June 5, 2017

SVP of Minerva just cashed-in 21,631 options - June 5, 2017

Submission of Matters to a Vote of Security Holders - June 2, 2017

Minerva Announces Amended Agreement For MIN-202 IN INSOMNIA - May 31, 2017

Minerva Announces Outcome Of End-Of-Phase 2 Meeting With Fda - May 15, 2017

Minerva Just Filed Its Quarterly Report: NOTE 4 — NET LOSS P... - May 4, 2017

Minerva releases salary data. CEO sees compensation fall -12% - April 18, 2017

Minerva: Form, Schedule Or Registration Statement No Filing Party: Date Filed: - April 18, 2017

Minerva director just picked up 50,000 shares - March 21, 2017

Pursuant to the requirements of the Securities Exchange Act of - March 21, 2017

Minerva Just Filed Its Annual Report: NOTE 5 — NET LOSS P... - March 13, 2017

Securities to be offered to employees in employee benefit plans - March 13, 2017

Current report, items 8.01 and 9.01 - Feb. 27, 2017

James D. Dondero just provided an update on share ownership of Minerva - Feb. 10, 2017

EVP of Minerva just disposed of 21,450 shares - Feb. 7, 2017

Minerva's President & CEO just cashed-in 34,281 options - Feb. 7, 2017

Bihua Chen just provided an update on share ownership of Minerva - Feb. 3, 2017

Minerva: Additional Data Analyses From Phase Iib Trial Of MIN-101 SCHIZOPHRENIA UNDERSCORE BENEFIT IN MULTIPLE MEASUREMENTS OF COGNITIVE FUNCTION - Jan. 20, 2017

Minerva's SVP & Chief Operating Officer just cashed-in 1,600 options - Jan. 13, 2017

SVP of Minerva just cashed-in 17,500 options - Jan. 6, 2017

Current report, items 8.01 and 9.01 - Jan. 6, 2017

Minerva's Chief Medical Officer was just granted 145,000 options - Jan. 5, 2017

SVP of Minerva just disposed of 5,000 shares - Dec. 29, 2016

Minerva's Chief Medical Officer just declared 30,000 options - Dec. 20, 2016

Minerva's President & CEO was just granted 225,000 options and restricted shares - Dec. 16, 2016

EVP of Minerva was just granted 150,000 options and restricted shares - Dec. 16, 2016

Minerva's SVP & Chief Operating Officer was just granted 95,000 options and restricted shares - Dec. 16, 2016

SVP of Minerva was just granted 55,000 options and restricted shares - Dec. 16, 2016

SVP of Minerva was just granted 55,000 options and restricted shares - Dec. 16, 2016

Departure of Directors or Certain - Dec. 16, 2016

Major owner of Minerva just picked up 202,634 shares - Dec. 14, 2016

Major owner of Minerva just picked up 202,634 shares - Dec. 14, 2016

Major owner of Minerva just picked up 202,634 shares - Dec. 14, 2016

Minerva Neurosciences’ Clinical Data Featured At The AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING - Dec. 5, 2016

Minerva Just Filed Its Quarterly Report: NOTE 4 — NET LOSS P... - Nov. 3, 2016

Minerva Neurosciences Announces Positive Data From Six-Month EXTENSION OF PHASE IIB TRIAL OF MIN-101 MONOTHERAPY IN SCHIZOPHRENIA - Oct. 26, 2016

Yucca just provided an update on activist position in Minerva - Sept. 27, 2016

Major owner of Minerva just disposed of 1,000,000 shares - Aug. 12, 2016

Major owner of Minerva just disposed of 1,000,000 shares - Aug. 12, 2016

Major owner of Minerva just disposed of 1,000,000 shares - Aug. 12, 2016

Minerva Just Filed Its Quarterly Report: NOTE 4 — NET LOSS P... - Aug. 4, 2016

Minerva director just picked up 55,635 shares - June 21, 2016

Minerva director was just granted 12,500 options - June 17, 2016

Minerva director was just granted 12,500 options - June 17, 2016

Minerva director was just granted 12,500 options - June 17, 2016

Minerva director was just granted 12,500 options - June 17, 2016

Minerva director was just granted 12,500 options - June 17, 2016

Submission of Matters to a Vote of Security - June 17, 2016

Minerva just filed a prospectus, suggesting it plans to soon issue some securities - June 14, 2016

Minerva Neurosciences Announces Proposed Public Offering Of Common Stock - June 14, 2016

Minerva just filed a prospectus, suggesting it plans to soon issue some securities - June 13, 2016

Current report, items 8.01 and 9.01 - June 13, 2016

Current report, items 8.01 and 9.01 - June 6, 2016

Minerva Neurosciences Announces Positive Results From Phase Iib Trial OF MIN-101 MONOTHERAPY IN SCHIZOPHRENIA - May 26, 2016

Quarterly report [Sections 13 or 15(d)] - May 3, 2016

Minerva: Form, Schedule Or Registration Statement No Filing Party: Date Filed: - April 29, 2016

Minerva releases salary data. CEO sees compensation fall -75% - April 29, 2016

Minerva just filed a prospectus, suggesting it plans to soon issue some securities - April 11, 2016

Care Capital III LLC just provided an update on activist position in Minerva - March 31, 2016

Notice of Exempt Offering of Securities, item 06b - March 18, 2016

Entry Into a Material Definitive - March 18, 2016

Minerva director just picked up 181,488 shares - March 18, 2016

Minerva Just Filed Its Annual Report: NOTE 5 — NET LOSS P... - March 14, 2016

Securities to be offered to employees in employee benefit plans - March 14, 2016

Minerva Neurosciences Announces Positive Top Line Results FROM PHASE IB CLINICAL TRIAL IN MAJOR DEPRESSIVE DISORDER WITH MIN-202 - March 11, 2016

Entry into a Material Definitive - Feb. 25, 2016

Minerva Neurosciences Announces Completion Of Patient Enrollment IN PHASE IIA TRIAL OF MIN-117 IN MAJOR DEPRESSIVE DISORDER - Feb. 22, 2016

Johnson & Johnson Innovation-JJDC, Inc. EIN just provided an update on share ownership of Minerva - Feb. 12, 2016

Major owner of Minerva just picked up 607,903 shares - Feb. 12, 2016

J. Christopher Donahue just provided an update on share ownership of Minerva - Feb. 11, 2016

Minerva Neurosciences Announces Top Line Data From Min-202 Phase I CLINICAL STUDY IN JAPANESE PATIENTS - Feb. 1, 2016

Minerva just filed a prospectus, suggesting it plans to soon issue some securities - Jan. 22, 2016

Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 PHASE 2A CLINICAL TRIAL IN INSOMNIA DISORDER - Jan. 11, 2016

Pursuant to the requirements of the Securities Exchange Act of - Jan. 11, 2016

Minerva Neurosciences Announces Update On Min-101 Clinical DEVELOPMENT PROGRAM - Dec. 29, 2015

Minerva Achieves Enrollment Target In Phase Iib Trial With Min-101 - Dec. 18, 2015

Minerva Provides Year-End Update On Clinical Trials WITH THREE CENTRAL NERVOUS SYSTEM PRODUCT CANDIDATES - Dec. 9, 2015

SVP of Minerva was just granted 69,000 options - Dec. 8, 2015

Minerva director was just granted 25,000 options - Dec. 8, 2015

Minerva's President & CEO was just granted 320,000 options - Dec. 8, 2015

SVP of Minerva was just granted 69,000 options - Dec. 8, 2015

Minerva's SVP & Chief Operating Officer was just granted 69,000 options - Dec. 8, 2015

Minerva's EVP & Chief Financial Officer was just granted 175,000 options - Dec. 8, 2015

Minerva director just declared owning 0 shares of Minerva - Nov. 3, 2015

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. FEDERATED INVESTORS INC /PA/ 7,535,287 0.1 Sept. 30, 2017
2. FMR LLC 5,660,794 N/A Sept. 30, 2017
3. Johnson & Johnson EIN 3,892,256 N/A Dec. 31, 2015
4. HIGHLAND CAPITAL MANAGEMENT LP 1,937,902 0.3 Sept. 30, 2017
5. PRICE T ROWE ASSOCIATES INC /MD/ 1,666,709 N/A Sept. 30, 2017
6. Care Capital III LLC 1,534,098 N/A March 22, 2016
7. VANGUARD GROUP INC 1,258,749 N/A Sept. 30, 2017
8. FRANKLIN RESOURCES INC 1,192,300 N/A Sept. 30, 2017
9. ASCEND CAPITAL, LLC 781,688 N/A Sept. 30, 2017
10. SPHERA FUNDS MANAGEMENT LTD. 625,000 0.7 Sept. 30, 2017
11. Cormorant Asset Management, LLC 607,903 0.8 Sept. 30, 2017
12. NEXTHERA CAPITAL LP 536,899 1.0 Sept. 30, 2017
13. BlackRock Fund Advisors 528,331 N/A Sept. 30, 2016
14. JPMORGAN CHASE & CO 388,300 N/A Sept. 30, 2017
15. State Street Corp 387,047 N/A Sept. 30, 2017
16. BlackRock Institutional Trust Company, N.A. 302,650 N/A Dec. 31, 2016
17. NORTHERN TRUST CORP 298,507 N/A June 30, 2017
18. GEODE CAPITAL MANAGEMENT, LLC 269,938 N/A Sept. 30, 2017
19. Artal Group S.A. 251,300 N/A Sept. 30, 2017
20. MILLENNIUM MANAGEMENT LLC 249,026 N/A Sept. 30, 2017
21. EcoR1 Capital, LLC 223,802 0.4 June 30, 2017
22. RENAISSANCE TECHNOLOGIES LLC 205,600 N/A Sept. 30, 2017
23. DAFNA Capital Management LLC 171,094 0.8 Sept. 30, 2017
24. J. Goldman & Co LP 156,717 N/A Sept. 30, 2017
25. TIAA CREF INVESTMENT MANAGEMENT LLC 144,796 N/A Sept. 30, 2017
26. BRIDGEWAY CAPITAL MANAGEMENT INC 141,000 N/A Sept. 30, 2017
27. Nationwide Fund Advisors 124,990 N/A Sept. 30, 2017
28. Handelsbanken Fonder AB 95,000 N/A Sept. 30, 2017
29. Bank of New York Mellon Corp 90,929 N/A June 30, 2017
30. Bank of New York Mellon Corp 90,929 N/A June 30, 2017

Minerva (NERV)

140
 


Feedback